An Open, Multicenter Phase II Study to Evaluate the Safety & Efficacy of

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06018129` - A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma	Phase 1/Phase 2
Recruiting	`NCT03212404` - Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers	Phase 1
Recruiting	`NCT04288726` - Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas	Phase 1
Recruiting	`NCT04486391` - Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma	Phase 3
Active, not recruiting	`NCT05008224` - Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)	Phase 2
Active, not recruiting	`NCT02684708` - Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents	Phase 3
Active, not recruiting	`NCT03226249` - PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma	Phase 2
Active, not recruiting	`NCT03739619` - Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma	Phase 1/Phase 2
Completed	`NCT03327571` - B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes
Recruiting	`NCT03652441` - Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma	Phase 2
Completed	`NCT02243436` - Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma	Phase 1/Phase 2
Terminated	`NCT04254107` - A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer	Phase 1
Recruiting	`NCT05714553` - NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours	Phase 1/Phase 2
Completed	`NCT02981914` - Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation	Early Phase 1
Withdrawn	`NCT04952584` - Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas	Phase 1
Withdrawn	`NCT03205891` - Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas	Phase 1
Not yet recruiting	`NCT02808520` - Social Inequalities in the Participation and Activity in Children and Adolescents With Hodgkin-lymphoma	N/A
Recruiting	`NCT02332668` - A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)	Phase 1/Phase 2
Completed	`NCT04858568` - Immune Responses to COVID-19 Vaccination in Lymphoma Patients
Active, not recruiting	`NCT02824029` - Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma	Phase 2

NCT number	NCT03580564
Study type	Interventional
Source	Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Contact
Status	Completed
Phase	Phase 2
Start date	August 1, 2018
Completion date	January 13, 2022

An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms